{"id":155721,"date":"2023-11-03T06:59:05","date_gmt":"2023-11-03T10:59:05","guid":{"rendered":"https:\/\/44.250.171.167\/?p=155721"},"modified":"2023-11-03T06:59:07","modified_gmt":"2023-11-03T10:59:07","slug":"dr-lal-pathlabs-ltd-q2-fy24-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2-fy24-earnings-conference-call-insights\/","title":{"rendered":"Dr Lal PathLabs Ltd Q2 FY24 Earnings Conference Call Insights"},"content":{"rendered":"<p><strong>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY24 Earnings Concall<\/strong><\/p>\n<ul>\n<li><strong>Financial Performance<\/strong>\n<ul>\n<li>Revenue for Q2 FY24 was INR601 crores, up 12.6% vs last year.<\/li>\n<li>EBITDA for Q2 was INR178 crores, margin of 29.6% vs 26.9% last year.<\/li>\n<li>Profit after tax was INR111 crores, margin of 18.4% vs 13.6% last year.<\/li>\n<li>EPS for Q2 was INR13.2, up 53% vs last year.<\/li>\n<li>Gross margins at 79.6% in Q2, highest historically, driven by price increases and operational efficiencies.<\/li>\n<li>Expect gross margins to be about 75% sustainably.<\/li>\n<li>Strong growth led by price increases, test mix, Swasthfit portfolio.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Business Growth Drivers<\/strong>\n<ul>\n<li>Market activation across geographies including Suburban Diagnostics.<\/li>\n<li>Investments in 35 hub labs enabling better TAT and market share gains.<\/li>\n<li>Expansion in tier 3\/4 towns showing good results, accelerating with 20 plus new labs.<\/li>\n<li>Focus on product portfolio like Swasthfit and ProSelf driving growth.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Operational Efficiency<\/strong>\n<ul>\n<li>Optimization across cost line items and reimagining value chain.<\/li>\n<li>New logistics app implemented, enhancing capabilities.<\/li>\n<li>Inventory holding reduced to 31 days.<\/li>\n<li>Debtor days at 28 days of credit sales.<\/li>\n<li>ROCE at 25.3% and CapEx of INR27 crores in H1 FY24 on new infra and technology.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Testing Volumes<\/strong>\n<ul>\n<li>5 million patients served in Q2, up 5.2% vs last year.<\/li>\n<li>2 million samples tested, up 11%.<\/li>\n<li>Covid contribution now only 22% of revenues.<\/li>\n<li>COVID testing now only 2% of revenues vs 38% last year.<\/li>\n<li>Non-COVID base business remains robust at 98% of revenues.<\/li>\n<li>Volumes recovering well on non-COVID tests.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Growth Strategy<\/strong>\n<ul>\n<li>Leveraging strong brand in North\/East India.<\/li>\n<li>Expanding in South\/West India through Suburban Diagnostics.<\/li>\n<li>Targeting underpenetrated tier 3\/4 towns and collection centers.<\/li>\n<li>Growing portfolio of specialized tests.<\/li>\n<li>Investing in technology and automation.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Business in Tier 3\/4 Markets<\/strong>\n<ul>\n<li>Company follows government classification for tier 3\/4 towns.<\/li>\n<li>Planning to open 20+ new labs in tier 3\/4 towns.<\/li>\n<li>Will expand collection center network alongside new labs.<\/li>\n<li>Margins should not be materially impacted as cost structure is competitive.<\/li>\n<li>This expansion is part of the normal business model.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Revenue Growth Outlook<\/strong>\n<ul>\n<li>Seeing steady improvement in volume and value growth recently.<\/li>\n<li>Growth rebounding to early teens levels after dip during pandemic.<\/li>\n<li>Volume growth recovering well excluding COVID testing.<\/li>\n<li>Value growth aided by pricing and mix, but underlying volume picking up.<\/li>\n<li>Expect to sustain volume\/value growth in early teens.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Suburban Diagnostics Traction and Outlook<\/strong>\n<ul>\n<li>Seeing first signs of growth after stabilization over past 1.5 years.<\/li>\n<li>Shifted to more franchisee-driven model vs own assets earlier.<\/li>\n<li>Addressed high employee turnover issues.<\/li>\n<li>Focus remains on Mumbai, Pune and Goa within Maharashtra.<\/li>\n<li>Suburban strategically important for LPL to expand in Western region.<\/li>\n<li>Aims to build suburban into a significant part of overall business.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Markets Update<\/strong>\n<ul>\n<li>Suburban had presence in Indore, Jabalpur and Rewa earlier.<\/li>\n<li>Decision taken to exit MP as LPL already has strong presence there.<\/li>\n<li>Will maintain minimal presence in MP but no major investments.<\/li>\n<li>Building up suburban for Western region and South later.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Omni-Channel Strategy<\/strong>\n<ul>\n<li>Presence across B2B and B2C channels.<\/li>\n<li>Offerings tailored based on healthcare ecosystem in each geography.<\/li>\n<li>Right mix of B2B and B2C for tier 3 expansion.<\/li>\n<li>Not overly dependent on any one channel.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Expansion Costs<\/strong>\n<ul>\n<li>Franchisee collection centers fund expansion, up to 45-46% of revenues.<\/li>\n<li>Revenue share to centers increasing due to mix, not rates.<\/li>\n<li>New labs in Tier 3 breakeven at INR2.5 cr revenue with 30% share.<\/li>\n<li>May see short term dilution but sustainable long term model.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Margin Outlook<\/strong>\n<ul>\n<li>Current high margins not sustainable long term.<\/li>\n<li>Will see impact from new lab investments.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY24 Earnings Concall Financial Performance Revenue for Q2 FY24 was INR601 crores, up 12.6% vs last year. EBITDA for Q2 was INR178 crores, margin of 29.6% vs 26.9% last year. Profit after tax was INR111 crores, margin of 18.4% vs 13.6% last year. EPS for Q2 [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":154818,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[8665,10169,8160],"class_list":["post-155721","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-diagnostics","tag-earnings","tag-healthcare-services"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/10\/CC_Image_1.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":136294,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":155721,"position":0},"title":"Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2022","format":false,"excerpt":"https:\/\/youtu.be\/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired about 2Q23 performance according to the company\u2019s expectations. Arvind Lal EC said the company\u2019s opinion is that the performance is slightly in line with what it was doing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172310,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-q2-fy26-earnings-results\/","url_meta":{"origin":155721,"position":1},"title":"Dr Lal Pathlabs Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 11, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lal Pathlab Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":129608,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":155721,"position":2},"title":"Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 18, 2022","format":false,"excerpt":"https:\/\/youtu.be\/XGfFd6kLFCE Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":155721,"position":3},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145982,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":155721,"position":4},"title":"Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 12, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:17:48] Rahul Agarwal from InCred Capital asked if 13-14% revenue growth can be seen next year, given the supportive base, low employee attrition, and faster growth outside Delhi NCR. Om Prakash MD said FY '23 was\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":170749,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-q1-fy26-earnings-results\/","url_meta":{"origin":155721,"position":5},"title":"Dr Lal Pathlabs Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 28, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Dr Lal Pathlab Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/8-6.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/8-6.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/8-6.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/8-6.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/8-6.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/8-6.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/155721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=155721"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/155721\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/154818"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=155721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=155721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=155721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}